ALPS Advisors’s ProQR Therapeutics PRQR Stock Holding History

ALPS Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-73,790	Closed	-$67K	–	1081
2022 Q1	$67K	Sell	73,790 -8,548	-10%	-$28.6K	﹤0.01%	832
2021 Q4	$660K	Buy	+82,338	New	+$627K	0.01%	452
2021 Q2	–	Sell	-90,714	Closed	-$600K	–	915
2021 Q1	$600K	Buy	90,714 +1,152	+1%	+$5.89K	0.01%	477
2020 Q4	$376K	Buy	89,562 +25,615	+40%	+$108K	﹤0.01%	570
2020 Q3	$306K	Sell	63,947 -4,219	-6%	-$22.1K	﹤0.01%	512
2020 Q2	$414K	Buy	+68,166	New	+$368K	0.01%	475
2019 Q4	–	Sell	-77,479	Closed	-$446K	–	850
2019 Q3	$446K	Sell	77,479 -3,871	-5%	-$30.9K	﹤0.01%	507
2019 Q2	$740K	Buy	+81,350	New	+$960K	0.01%	411

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ALPS Advisors's PRQR Position: Q2 2022 in Review

ALPS Advisors sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 73,790 shares — an estimated $67K sold.

ALPS Advisors first reported a position in PRQR in Q2 2019 and held it in 8 quarters. The position peaked at $740K in Q2 2019. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

ALPS Advisors reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
ALPS Advisors sold 73,790 ProQR Therapeutics shares in Q2 2022, an estimated $67K.
ALPS Advisors first reported a position in ProQR Therapeutics in Q2 2019 and held it in 8 quarters.
ALPS Advisors's ProQR Therapeutics position peaked at $740K in Q2 2019.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.